Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;43(2):122-128.
doi: 10.1002/phar.2760. Epub 2023 Jan 16.

Levetiracetam-associated behavioral adverse events in neurocritical care patients

Micheal Strein  1 , John P Holton-Burke  2 , Spiro Stilianoudakis  3 , Carley Moses  4 , Sulaiman Almohaish  1   5 , Gretchen M Brophy  1
Affiliations

Levetiracetam-associated behavioral adverse events in neurocritical care patients

Micheal Strein et al. Pharmacotherapy. 2023 Feb.

Abstract

Study objectives: The objective of this study was to identify the incidence of levetiracetam-associated BAEs in NCC patients.

Design: Single-center retrospective cohort analysis.

Data source: Patient charts.

Patients: 965 adult ICU patients with a neurological injury receiving levetiracetam that were admitted to an intensive care unit.

Measurements and main results: There were 965 patients included; 52% males with a median GCS of 13. Injury types included TBI (43.1%), ICH (21.8%), SAH (20.5%), and CI (14.6%). BAEs were identified in 46% of patients. Of these, 60% had documentation of agitation/restlessness, delirium, or anxiety while receiving levetiracetam, only 25% had a positive CAM-ICU, 13% had restraints ordered, and 42% received antipsychotics. Patients with TBI had the highest incidence of BAEs (52.4%). The median time to initiation of levetiracetam after hospital admission was 6.4 hours and BAEs occurred after 1.3 days of levetiracetam initiation.

Conclusions: In this study, we found that almost half of our NCC population experienced levetiracetam associated BAEs which were mostly hyperactive in nature. We believe that the incidence of BAEs in our specific patient population cannot solely be attributed to ICU delirium given the lower risk of developing hyperactive delirium in ICU patients as compared to other subtypes. Therefore, monitoring and determination of the benefit versus risk in those experiencing BAEs is highly encouraged.

Keywords: adverse event; agitation; behavioral adverse event; delirium; levetiracetam; neurocritical care.

PubMed Disclaimer

References

REFERENCES

    1. Fukuyama K, Tanahashi S, Nakagawa M, et al. Levetiracetam inhibits neurotransmitter release associated with CICR. Neurosci Lett. 2012;518:69-74.
    1. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101:9861-9866.
    1. Carunchio I, Pieri M, Ciotti MT, Albo F, Zona C. Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia. 2007;48:654-662.
    1. Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure. 2007;16:296-304.
    1. Werhahn KJ, Trinka E, Dobesberger J, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia. 2015;56:450-459.

Publication types

Grants and funding

LinkOut - more resources